公开(公告)号：US20240139280A1

公开(公告)日：2024-05-02

申请号：US18286334

申请日：2022-04-13

申请人： ONCOC4, INC. ,  University of Maryland, Baltimore

发明人： Yin Wang ,  Yang Liu ,  Pan Zheng ,  Martin Devenport ,  Yan Liu ,  Christopher Bailey

IPC分类号： A61K38/12 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K38/12 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/505

摘要： The present invention relates to the use of hypoxia-inducible factor (HIF) inhibitors in cancer immunotherapy. Specifically, the disclosure provides methods of treating a cancer in a subject in need of cancer immunotherapy, comprising administering a HIF-1a inhibitor to the subject and a second cancer immunotherapeutic agent to the subject, wherein the HIF-1a inhibitor comprising echinomycin, and wherein the second cancer immunotherapeutic agent comprising an anti-CTLA-4 antibody including Ipilimumab or Tremelimumab.